Global High Content Screening (HCS) Industry

  • July 2012
  • -
  • Global Industry Analysts
  • -
  • 486 pages

This report analyzes the worldwide markets for High Content Screening (HCS) in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. The report profiles 50 companies including many key and niche players such as BD Biosciences, BioTek Instruments Inc., CompuCyte Corporation, CM Technologies Oy, Definiens AG, EMD Millipore, EVOTEC BioSystems, Essen BioScience, Fluxion Biosciences, Inc., GE Healthcare Life Sciences, Genedata AG, IntelliCyt Corporation, Life Technologies Corporation, Molecular Devices Inc., PerkinElmer Inc., Roche Applied Science, Thermo Fisher Scientific, Inc., TTP LabTech Ltd., and Yokogawa Electric Corporation. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.

Table Of Contents



I. INTRODUCTION, METHODOLOGY and PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation and Reporting Level I-2
Quantitative Techniques and Analytics I-3
Product Definitions and Scope of Study I-3


II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW II-1
A Prelude II-1
Key Growth Drivers II-1
Key Challenges II-1
High Content Screening - An Outlook II-2
Assessing HCS Success So Far II-2
Current and Future Analysis II-2
HCS - A Rapidly Expanding Screening Technology II-2
Recession in Pharma Industry Hits Prospects for Consumables
and Instruments II-3
HCS vs. HTS II-3
Competitive Overview II-4
Noteworthy HCS Product Innovations by Select Market Leaders II-4
Table 1: Leading Players in the Global HCS Market (2011):
Percentage Share Breakdown for Thermo Fisher Scientific, GE
Healthcare, PerkinElmer, Molecular Devices, Life Technologies
Corporation, BD Biosciences, Compucyte and Others (includes
corresponding Graph/Chart) II-5

Table 2: Leading Players in the Global Screening Market
(2010): Percentage Breakdown of Market Share for Molecular
Devices, Thermo Fisher (Cellomics), GE/Amersham, Evotec, BD
Biosciences and Others (includes corresponding Graph/Chart) II-6

2. MARKET TRENDS AND ISSUES II-7
HCS No Longer a Secondary Screening Method II-7
Table 3: Global Screening Market (2011): Percentage Share
Breakdown by Segment - Primary Screening, Secondary Screening
and Leads-to-Candidate (ADME/Tox Screening) (includes
corresponding Graph/Chart) II-7
High Instrumentation Costs Hamper Rapid Growth II-7
Instrumentation - A Vital Component of the HCS Market II-8
Table 4: Global Market for High Content Screening (2011):
Percentage Share Breakdown by Segments - Instruments,
Reagents, Assay Services, HCS Service and Software (includes
corresponding Graph/Chart) II-8
Emergence of Academic Sector as the Major User of HCS II-8
Table 5: HCS Budget of a Typical Research Company (includes
corresponding Graph/Chart) II-9
Need for Enhanced Quantitative Measurements for New Cell Types II-9
HCS Specific Data Analysis Systems - The Need of the Hour II-9

3. HCS APPLICATION AREAS II-11
HCS in Drug Discovery II-11
Target Discovery II-11
Hit Identification II-11
Lead Development II-11
HCS for Screening of Nano Materials in Zebra Fish II-11
High Content Screening in Life Sciences Research II-12
High Content Screening - Key Application Areas II-12
Table 6: Global Cell Analysis Instrumentation Market (2011):
Percentage Share Breakdown by Segments - High Content
Screening and Others (includes corresponding Graph/Chart) II-12

Table 7: Global Life Science Instrumentation Market (2011):
Percentage Share Breakdown by Technologies - PCR, Nucleic
Acid Prep and Cell Separation, Microarrays, Sequencers
(Nucleic Acid, Protein), Flow Cytometry, Electrophoresis,
Synthesizers (Nucleic
Acid, Protein, Organic), In Vivo
Animal Imaging, Informatics, High Content Screening,
Label-Free Detection and Electrophysiology/ Patch Clamp
(includes corresponding Graph/Chart) II-13
HCS and Oncology II-13
HCS and Neurobiology II-14
HCS and In Vitro Toxicology II-14

4. PRODUCT OVERVIEW II-15
Defining High Content Screening II-15
The Process of High Content Screening II-15
Technology Evolves Over the Years II-17
HCS Tools II-17
List of HCS Tools II-17
HCS Imaging - Categories II-18
Instrumentation II-18

5. PRODUCT INTRODUCTIONS/INNOVATIONS II-19
Molecular Devices Rolls Out New Digital Confocal Module for
ImageXpress® HCS Systems II-19
PerkinElmer to Unveil Columbusâ„¢ 2.3 Image Data Storage and
Analysis System II-19
PerkinElmer Rolls Out HCA ImagAmpâ„¢ Reagent Kit for High
Content Analysis II-20
Molecular Devices Launches ImageXpress® Micro XL Screening System II-20
Cellomics Introduces Certified ArrayScan® HCS Reader II-20
PerkinElmer Launches Enhanced Software and Hardware Features
for Opera® High Content Screening System II-21
PerkinElmer Unveils Volocity 6.0 3D Cellular Imaging Software
Line II-21
Thermo Fisher Introduces Software and Hardware Enhancements
for HCS Reader II-22
Thermo Fisher Scientific Launches CellInsight, Personal Cell
Imager II-22
BellBrook Labs Unveils iuvo Chemotaxis Assay Plate II-23
TTP LabTech Introduces Mirrorballâ„¢ System, a Microplate Cytometer II-23
Leica Microsystems Launches Content Screening Automation Package II-23
CYTOO Cell Architects Introduces CYTOOplatesâ„¢ 96 II-24
AMS Biotechnology Introduces Orisâ„¢ Pro 384 Cell Migration Assay II-24
TTP LabTech Introduces Contract Screening Service II-25
BellBrook Labs Introduces Novel Invasion Assay Service II-25
Thermo Fisher Scientific Unveils High Content 2.0 II-25
Thermo Fisher Scientific Launches Cellomics Synaptogenesis HCS
Assay Reagent Kit II-26
GE Healthcare Introduces IN Cell Analyzer 2000 II-26
MDS Analytical Introduces New Cellular Imaging Software II-27
CompuCyte Introduces Four New Laser Imaging Cytometers II-27
DiscoveRx Launches New Products and Services for Expanding Its
GPCR Assay Portfolio II-27
TTP LabTech Introduces Mosquito® LCP System for Screening
Services II-28
TTP LabTech Introduces Novel Platform Solutions for
Cytotoxicity Studies II-28
PerkinElmer Introduces Columbus 2.0, HCS Data Management Software II-28
BD Biosciences Introduces BD PureCoat Cell Culture Surfaces II-29
Thermo Fisher Scientific Launches Cellomics HCSDiscover Data
Mining Tool II-29
Thermo Fisher Scientific Introduces High Content Screening Kits II-29
PerkinElmer Introduces Operetta System, a Benchtop HCS/HCA
Instrument II-30
Caliper Discovery Alliances and Services Introduces GPCR Assay
Technology II-30

6. RECENT INDUSTRY ACTIVITY II-31
Yokogawa Inks Marketing Agreement with Wako Pure Chemical II-31
Myomics and InvivoSciences Enter into Alliance II-31
SYGNIS Bioscience and Cenix BioScience Ink Research Agreement II-31
Cyprotex Adds Automated HCS Implementation Service to Portfolio II-32
Definiens and Leica Microsystems Sign Co-Marketing Agreement II-32
Molecular Devices Inks Agreement with Adtech-GESI II-32
Molecular Devices Signs Licensing Agreement with De Novo Software II-33
PerkinElmer Takes Over VisEn Medical II-33
Eisai Enters into Collaboration with Forma Therapeutics II-34
Shrink Nanotechnologies Enters into Agreement to Develop Stemageâ„¢ II-34
Essen Instruments Undergoes Name Change to Essen BioScience II-34
Rigel Pharmaceuticals Selects HighRes Biosolutions for
Screening Automation II-35
Cyprotex Adds Thermo Scientific Cellomics ArrayScan® VTI HCS
Reader II-35
Danaher Takes Over Molecular Devices and AB SCIEX II-35
DiscoveRx Takes Over KINOMEscanâ„¢ II-35
HD Biosciences Signs Partnership Agreement with DiscoveRx II-36
Jubilant Biosys Signs Co-marketing Agreement with DiscoveRx
for Providing Screening Services II-36
PerkinElmer Enters into Collaboration with IDBS II-36
Fluofarma Signs Agreement with Hoffmann-La Roche II-37
VistaGen Therapeutics Enters into Agreement with Capsant II-37
DiscoveRx Inks Co-marketing Agreement with Evotec II-37
DiscoveRx Inks Co-Marketing Agreement with Biofocus II-37
DiscoveRx Sign Global Agreement with Glaxo SmithKline II-38
MDS Analytical Technologies Takes Over Blueshift Biotechnologies II-38

7. FOCUS ON SELECT GLOBAL PLAYERS II-39
BD Biosciences (US) II-39
BioTek Instruments Inc (US) II-39
CompuCyte Corporation (US) II-39
CM Technologies Oy (Finland) II-40
Definiens AG (Germany) II-40
EMD Millipore (US) II-40
EVOTEC BioSystems (Germany) II-41
Essen BioScience (US) II-41
Fluxion Biosciences, Inc. (US) II-41
GE Healthcare Life Sciences (Sweden) II-41
Genedata AG (Switzerland) II-42
IntelliCyt Corporation (US) II-42
Life Technologies Corporation (US) II-42
Molecular Devices Inc. (US) II-43
PerkinElmer Inc (US) II-43
Roche Applied Sciences (Germany) II-44
Thermo Fisher Scientific, Inc. (US) II-44
TTP LabTech Ltd. (UK) II-44
Yokogawa Electric Corporation (Japan) II-45

8. GLOBAL MARKET PERSPECTIVE II-46
Table 8: World Recent Past, Current and Future Analysis for High
Content Screening by Geographic Region - US, Canada, Japan,
Europe and Rest of World Markets Independently Analyzed with
Annual Revenues in US$ Million for Years 2010 through 2018
(includes corresponding Graph/Chart) II-46

Table 9: World Historic Review for High Content Screening by
Geographic Region - US, Canada, Japan, Europe and Rest of
World Markets Independently Analyzed with Annual Revenues in
US$ Million for Years 2004 through 2009 (includes
corresponding Graph/Chart) II-47

Table 10: World 15-Year Perspective for High Content Screening -
Percentage Breakdown of Dollar revenues by Geographic Region -
US, Canada, Japan, Europe and Rest of World for Years 2004,
2011 and 2018 (includes corresponding Graph/Chart) II-48


III. MARKET

1. THE UNITED STATES III-1
A.Market Analysis III-1
Outlook III-1
Market Overview III-1
Product Introductions/Innovations III-1
Recent Industry Activity III-11
Key Players III-16
B.Market Analytics III-21
Table 11: US Recent Past, Current and Future Analysis for High
Content Screening Market Independently Analyzed with Annual
Revenues in US$ Million for Years 2010 through 2018
(includes corresponding Graph/Chart) III-21

Table 12: US Historic Review for High Content Screening
Market Independently Analyzed with Annual Revenues in US$
Million for Years 2004 through 2009 (includes corresponding
Graph/Chart) III-22

2. CANADA III-23
A.Market Analysis III-23
Outlook III-23
B.Market Analytics III-23
Table 13: Canadian Recent Past, Current and Future Analysis
for High Content Screening Market Independently Analyzed
with Annual Revenues in US$ Million for Years 2010 through
2018 (includes corresponding Graph/Chart) III-23

Table 14: Canadian Historic Review for High Content
Screening Market Independently Analyzed with Annual Revenues
in US$ Million for Years 2004 through 2009 (includes
corresponding Graph/Chart) III-24

3. JAPAN III-25
A.Market Analysis III-25
Outlook III-25
Recent Industry Activity III-25
Key Player III-26
B.Market Analytics III-26
Table 15: Japanese Recent Past, Current and Future Analysis
for High Content Screening Market Independently Analyzed
with Annual Revenues in US$ Million for Years 2010 through
2018 (includes corresponding Graph/Chart) III-26

Table 16: Japanese Historic Review for High Content
Screening Market Independently Analyzed with Annual Revenues
in US$ Million for Years 2004 through 2009 (includes
corresponding Graph/Chart) III-27

4. EUROPE III-28
A.Market Analysis III-28
Outlook III-28
Product Introductions/Innovations III-28
Recent Industry Activity III-30
Key Players III-32
B.Market Analytics III-35
Table 17: European Recent Past, Current and Future Analysis
for High Content Screening Market Independently Analyzed
with Annual Revenues in US$ Million for Years 2010 through
2018 (includes corresponding Graph/Chart) III-35

Table 18: European Historic Review for High Content
Screening Market Independently Analyzed with Annual Revenues
in US$ Million for Years 2004 through 2009 (includes
corresponding Graph/Chart) III-36

5. REST OF WORLD III-37
A.Market Analysis III-37
Outlook III-37
Select Regional Analysis III-37
Life Sciences Market in China Continues to Thrive Despite
Recession III-37
China Emerges as the Major Outsourcer for Drug Discovery III-37
Few Problem Areas Exist III-38
Need of the Hour III-38
B.Market Analytics III-39
Table 19: Rest of World Recent Past, Current and Future
Analysis for High Content Screening Market Independently
Analyzed with Annual Revenues in US$ Million for Years 2010
through 2018 (includes corresponding Graph/Chart) III-39

Table 20: Rest of World Historic Review for High Content
Screening Market Independently Analyzed with Annual Revenues
in US$ Million for Years 2004 through 2009 (includes
corresponding Graph/Chart) III-40


IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 50 (including Divisions/Subsidiaries - 60)

The United States (30)
Canada (1)
Japan (2)
Europe (23)
- France (2)
- Germany (7)
- The United Kingdom (8)
- Rest of Europe (6)
Asia-Pacific (Excluding Japan) (4)

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

Enabling Technological Platforms for Lab-on-Chip Applications  (Technical Insights)

Enabling Technological Platforms for Lab-on-Chip Applications (Technical Insights)

  • $ 6 500
  • Industry report
  • June 2014
  • by Frost & Sullivan

6 Dimensional Assessment of Lab on a Chip Innovation Landscape A growing trend towards miniaturizing laboratory practices has been a major driving force behind the steady increase of innovations in the ...

Proteomics Markets for Research and IVD Applications

Proteomics Markets for Research and IVD Applications

  • $ 4 200
  • Industry report
  • September 2014
  • by Kalorama Information

This Kalorama Information report defines markets and identifies trends for proteomics applications, both in their research use and in IVD. Proteomics is the study of proteins, including the study of the ...

Biologicals in Oncology Drug Pipeline Update 2014

Biologicals in Oncology Drug Pipeline Update 2014

  • $ 3 749
  • Industry report
  • July 2014
  • by Bioseeker

This drug pipeline update covers a wide array of biological drugs, such as: antibodies,proteins, peptides, DNA, RNA and cellular therapies. There are today 908 companies plus partners developing 1686 biological ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.